Evidence map›Paper›PMID 31177305›Full record

Trial reportWorld journal of urology2020

Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial.

Ville Sell, Otto Ettala, Ileana Montoya Perez, Riikka Järvinen, Tarmo Pekkarinen, Markku Vaarala, Marjo Seppänen, Tapani Liukkonen, Timo Marttila, Sirpa Aaltomaa and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01675219 (Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01675219 phase3unknown statusnot on this map

Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9)

TypeinterventionalSponsorTurku University HospitalRan2012 to 2023Enrolled400ConditionsBladder CancerArmswhite light TUR-BT, blue light TUR-BT, optimized MMC, single immediate chemotherapy instillation
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. CD8Oncogene · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ville SellDepartment of Urology, Turku University Hospital, Turku, Finland. ville.sell@gmail.com.ORCID http://orcid.org/0000-0003-0899-5981
Otto EttalaDepartment of Urology, Turku University Hospital, Turku, Finland.
Ileana Montoya PerezDepartment of Future Technology, University of Turku, Turku, Finland.
Riikka JärvinenDepartment of Urology, Helsinki University Hospital, Helsinki, Finland.
Tarmo PekkarinenDepartment of Urology, Tampere University Hospital, Tampere, Finland.
Markku VaaralaDepartment of Urology, Oulu University Hospital, Oulu, Finland.
Marjo SeppänenDepartment of Surgery, Satakunta Central Hospital, Pori, Finland.
Tapani LiukkonenDepartment of Surgery, Mikkeli Central Hospital, Mikkeli, Finland.
Timo MarttilaDepartment of Surgery, Seinäjoki Central Hospital, Seinäjoki, Finland.
Sirpa AaltomaaDepartment of Urology, Kuopio University Hospital, Kuopio, Finland.
Eero KaasinenDepartment of Surgery, Hospital of Hyvinkää, Hyvinkää, Finland.
Peter J BoströmDepartment of Urology, Turku University Hospital, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the symptoms and delays in the clinical pathway of bladder cancer (BC).

methodsThis is a substudy of a prospective, randomized, multicenter phase III study (FinnBladder 9, NCT01675219) where the efficacy of photodynamic diagnosis and 6 weekly optimized mitomycin C instillations are studied in pTa bladder cancer with high risk for recurrence. The data of presenting symptoms and critical time points were prospectively collected, and the effect of factors on delays was analyzed.

resultsAt the time of analysis, 245 patients were randomized. Analysis included 131 patients with primary bladder cancer and their complete data. Sixty-nine percent had smoking history and 67% presented with macroscopic hematuria. Median patient delay (from symptoms to health-care contact) was 7 days. The median general practice delay (from health-care contact to urology referral) was 8 days. Median time from urology referral to cystoscopy was 23 days and from cystoscopy to TUR-BT 21 days. Total time used in the clinical pathway (from symptom to TUR-BT) was 78 days. Current and former smokers had non-significantly shorter patient-related and general practice delays compared to never smokers. TUR-BT delay was significantly shorter in patients with malignant cytology (16 days) compared to patients with benign cytology (21 days, p = 0.03).

conclusionsPatient-derived delay was short and most of the delay occurred in the referral centers. The majority had macroscopic hematuria as the initial symptom. Surprisingly, current and past smokers were more prone to contact the health-care system compared to never smokers.

Indexed as

Delayed DiagnosisRisk AssessmentAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesSymptom AssessmentUrinary Bladder NeoplasmsBladder cancerDiagnosisDiagnostic delayHematuriaSymptoms

Identifiers

PMID31177305
PMCPMC7154016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.